AutoGenomics IPO Will Support Trial Of HPV Test On Infiniti Analyzer
This article was originally published in The Gray Sheet
Executive Summary
AutoGenomics is seeking to fund a clinical study of its HPV-QUAD human papillomavirus screening test through an initial public stock offering worth up to $86.3 million (see chart: "1AutoGenomics IPO")